Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes

• DOI: 10.1186/s12985-021-01554-8
• Publication Date: 2021-04-28T17:03:59Z
• Authors: Lin Cheng; Shuo Song; Bing Zhou; Xiangyang Ge; Jiazhen Yu; Mingxia Zhang; Bin Ju; Zheng Zhang
• Keywords: 0301 basic medicine; N501Y variant; Neutralizing activity; Binding Sites; SARS-CoV-2; Short Report; Antibody Affinity; Antibodies, Monoclonal; Infectious and parasitic diseases; RC109-216; Antibodies, Viral; Antibodies, Neutralizing; Monoclonal neutralizing antibody; 3. Good health; Epitopes; 03 medical and health sciences; HEK293 Cells; Binding kinetics; Neutralization Tests; Mutation; Spike Glycoprotein, Coronavirus; Humans

Abstract The emergence and rapid spread of the B.1.1.7 lineage (VOC-202012/01) SARS-CoV-2 variant has aroused global concern. N501Y substitution is only mutation in interface between RBD ACE2, raising concerns that its recognition by neutralizing antibodies may be affected. Here, we assessed activity binding affinity a panel 12 monoclonal against wild type mutant pseudovirus protein, respectively. We found neutralization most detected (10 out 12) were unaffected, although decreased activities CB6 increased BD-23. These findings could value development therapeutic antibodies.